`
`Injectable (and intranasal-
`IN) generic
`
`Intranasal branded
`
`Injectable generic1
`
`Auto-injector branded
`
`Brand name
`
`Narcan Nasal Spray
`
`Evzio Auto-Injector
`
`Product comparison
`
`(Product not yet
`released2)
`
`FDA approved
`Labeling includes instructions
`for layperson use
`
`X (for IV, IM, SC)
`
`X
`X
`
`Assembly required
`
`Fragile
`
`Can titrate dose
`
`Strength
`
`X
`
`X
`
`X
`
`(yellow & purple)
`
`(blue & purple)
`
`(Formulation to
`be discontinued3)
`
`X
`X
`
`X
`
`X
`
`X
`
`1 mg/mL
`
`4 mg/0.1 mL
`
`2mg/0.1mL
`
`0.4 mg/mL
`
`4 mg/10 mL
`
`0.4 mg/0.4mL
`
`2 mg/0.4mL
`
`Storage requirements
`(All protect from light)
`
`Store at 59-86 °F
`Fragile: Glass.
`
`Store at 59-77 °F
`Excursions from 39-104 °F
`
`Store at 68-77 °F
`Breakable: Glass.
`
`Store at 59-77 °F
`Excursions from 39-104 °F
`
`Cost/kit4
`
`Refills
`
`Rx and quantity
`
`$$
`
`Two
`
`$$
`
`Prescription variation
`
`Two
`
`$
`
`Two
`
`$$$
`
`Two
`
`#2 2 mL Luer-Jet™ Luer-Lock
`needleless syringe plus #2
`mucosal atomizer devices
`(MAD-300)
`
`#1 two-pack
`of two 4
`mg/0.1 mL
`intranasal
`devices
`
`#1 four-pack
`of four 2
`mg/0.1 mL
`intranasal
`devices
`
`#2 single-use 1 mL
`vials PLUS #2 3 mL
`syringe w/ 23-25
`gauge 1-1.5 inch
`IM needles
`
`#1 10mL multidose
`vial PLUS #2 3 mL
`syringe w/ 23-25
`gauge 1-1.5 inch IM
`needles
`
`#1 two-pack of
`two 0.4 mg/0.4
`mL prefilled
`auto-injector
`devices
`
`#1 two-pack of
`two 2 mg/0.4 mL
`prefilled auto-
`injector devices
`
`PrescribeToPrevent.org
`
`April 2017
`
`Opiant Exhibit 2117
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 1
`
`
`
`Naloxone Product Comparison
`
`
`Injectable (and intranasal-
`IN) generic
`
`Intranasal branded
`
`Injectable generic1
`
`Auto-injector branded
`
`Sig. (for suspected opioid
`overdose)
`
`Spray 1 ml (1/2 of syringe)
`into each nostril. Repeat after
`2-3 minutes if no or minimal
`response.
`
`Spray 0.1 mL into one nostril.
`Repeat with second device
`into other nostril after 2-3
`minutes if no or minimal
`response.
`
`Inject 1 mL in shoulder or thigh. Repeat
`after 2-3 minutes if no or minimal
`response.
`
`Inject into outer thigh as directed
`by English voice-prompt system.
`Place black side firmly on outer
`thigh and depress and hold for 5
`seconds. Repeat with second
`device in 2-3 minutes if no or
`minimal response.
`
`Ordering information
`
`How supplied
`
`Box of 10 Luer-Jet™ prefilled
`glass syringes
`
`Two-pack of single use
`intranasal devices
`
`Manufacturer
`
`
`IMS/ Amphastar
`
`Teleflex
`(off-label IN
`adapter)
`
`Adapt Pharma
`
`
`Web address
`
`Amphastar.com
`
`Teleflex. com
`
`Narcannasalspray.com
`
`Customer service
`
`800-423-4136
`
`866-246-6990
`
`844-462-7226
`
`NDC
`
`
`
`76329-3369-01 DME- no NDC
`
`69547-353-02
`
`
`69547-212-04
`
`Box of 10 or
`package of 25
`single-dose fliptop
`vials (1 ml)
`
`Pfizer, Mylan and
`West-Ward
`Pharmaceuticals
`
`Pfizerinjectables.com
`Mylan.com
`West-ward.com
`
`877-946-7747 (P)
`724-514-1800 (M)
`800-631-2174 (W)
`
`00409-1215-01 (P)
`67457-0292-02 (M)
`0641-6132-25 (W)
`
`Case of 25 multi-
`dose fliptop vials
`(10 ml)
`
`Two pack of single use auto-
`injectors + 1 trainer
`
`Pfizer
`
`kaléo
`
`
`Pfizerinjectables.com
`
`Evzio.com
`
`877-946-7747 (P)
`
`855-773-8946
`
`00409-1219-01
`
`60842-030-01
`
`60842-051-01
`
` 1
`
` Pfizer acquired Hospira in 2015. Pfizer has an additional naloxone product, which is not recommended for layperson and take-home naloxone use because it is complicated to assemble. (Naloxone Hydrochloride
`Injection, USP, 0.4 mg/mL Carpuject™ Luer Lock Glass Syringe (no needle) NDC# 0409-1782-69)
`2 This product concentration is not yet currently available. As a result, some of the content is left blank.
`3 EVZIO 2 mg is now available. As of February 2017, EVZIO 0.4 mg will no longer be manufactured, but is still currently available and effective.
`4 There is considerable price variance for each product- local pharmacists are able to provide specific local pricing.
`Image development supported by 1R01DA038082-01 Friedmann/Rich
`
`
`
`PrescribeToPrevent.org
`
`April 2017
`
`Opiant Exhibit 2117
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 2
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
